GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Eli Lilly and Co (WBO:LLYC) » Definitions » EV-to-FCF

Eli Lilly and Co (WBO:LLYC) EV-to-FCF

: -237.27 (As of Today)
View and export this data going back to 2019. Start your Free Trial

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Eli Lilly and Co's Enterprise Value is €691,346 Mil. Eli Lilly and Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 was €-2,914 Mil. Therefore, Eli Lilly and Co's EV-to-FCF for today is -237.27.

The historical rank and industry rank for Eli Lilly and Co's EV-to-FCF or its related term are showing as below:

WBO:LLYC' s EV-to-FCF Range Over the Past 10 Years
Min: -3431.9   Med: 38.1   Max: 169.86
Current: -233.8

During the past 13 years, the highest EV-to-FCF of Eli Lilly and Co was 169.86. The lowest was -3431.90. And the median was 38.10.

WBO:LLYC's EV-to-FCF is ranked worse than
100% of 512 companies
in the Drug Manufacturers industry
Industry Median: 22.12 vs WBO:LLYC: -233.80

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-16), Eli Lilly and Co's stock price is €716.60. Eli Lilly and Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was €5.251. Therefore, Eli Lilly and Co's PE Ratio for today is 136.47.


Eli Lilly and Co EV-to-FCF Historical Data

The historical data trend for Eli Lilly and Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eli Lilly and Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 39.85 39.06 51.34 78.64 -182.68

Eli Lilly and Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-FCF Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 78.64 90.16 143.64 -3,199.88 -182.68

Competitive Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co EV-to-FCF Distribution

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's EV-to-FCF falls into.



Eli Lilly and Co EV-to-FCF Calculation

Eli Lilly and Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=691346.181/-2913.783
=-237.27

Eli Lilly and Co's current Enterprise Value is €691,346 Mil.
Eli Lilly and Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2,914 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eli Lilly and Co  (WBO:LLYC) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Eli Lilly and Co's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=716.60/5.251
=136.47

Eli Lilly and Co's share price for today is €716.60.
Eli Lilly and Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.251.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Eli Lilly and Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Eli Lilly and Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Eli Lilly and Co (WBO:LLYC) Business Description

Address
Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Eli Lilly and Co (WBO:LLYC) Headlines

No Headlines